Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.

Lin Zhao et al.PubMed ↗Full text ↗Publisher ↗

The primary results report of NCT05024032. Its numbers are set against the trial’s posted results below.

What the trial testedrandomised · 210 people · 2024

Randomised comparison

Probably lowered body weight & composition

Doesn’t vote: the registry posted this outcome, and its result counts

−11.3percentage points−14.3 to −8.30

As reported

difference −11.3 %, 95% CI −14.3 to −8.30

Randomised comparison

Probably lowered body weight & composition

Doesn’t vote: the registry posted this outcome, and its result counts

−15.1percentage points−18.2 to −12.1

As reported

difference −15.1 %, 95% CI −18.2 to −12.1

+1 more in the walkthrough ↓

Against the trial’s posted results

Same verdict as the posted result, different numberThis paper difference −15.1 (−18.2 to −12.1)Posted, primary outcome difference −17.5 (−20.3 to −14.8), p <0.001Mean Percent Change From Baseline in Body WeightAnother analysis of the same outcome: a different population, model or data cut. The trial counts once.
Same verdict as the posted result, different numberThis paper difference −11.3 (−14.3 to −8.30)Posted, primary outcome difference −12.0 (−14.8 to −9.30), p <0.001Mean Percent Change From Baseline in Body WeightAnother analysis of the same outcome: a different population, model or data cut. The trial counts once.

Three numbers in the abstract

the abstract, start to end

… change in body weight at week 52 was -13.6% (95% CI, -15.8% to -11.4%) with tirzepatide 10 mg, -17.5% (95% CI, -19.7% to -15.3%) with tirzepatide 15 mg, and -2.3% with placebo (difference between 10 mg and placebo, -11.3% [95% CI, -14.3% to -8.3%; P < .001]; difference between 15 mg and placebo, -15.1% [95% CI, -18.2% to -12.1%; …

← favours treatmentfavours comparator →

could be chance

Body weight & composition

−13.6−15.8 to −11.4

Body weight & composition

−11.3−14.3 to −8.30

Body weight & composition

−15.1−18.2 to −12.1

GIP/GLP-1 & amylin agonistsBody weight & composition

1 / 3

71 papers cite itlatest 60 shown

2024

…

2025

2026

this paperpooled ittrialcites it

The trial

NCT05024032phase 3210 enrolled2021this paper is its primary report

Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.

What the trial testedrandomised · 210 people · 2024

Probably lowered body weight & composition

Probably lowered body weight & composition

Against the trial’s posted results

Three numbers in the abstract

Where each one falls

Where it lands on the map

71 papers cite itlatest 60 shown

The trial